Trichomoniasis in adolescents : Safe and easy screening options Teens and confidentiality : Know the legal challenges in your state EHRs and your pediatric practice : What requirements and costs mean for you Oral contraceptive therapy for teens : 7 strategies for talking to parents who object Dermcase : Maffucci syndrome in a 10-year-old boy Puzzler : Upper extremity hemiparesis in toddler with seizures
Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up
September 21st 2023Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.
Roflumilast cream 0.05% safe, effective for children aged 2 to 5 years with atopic dermatitis
September 20th 2023Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years.
2 Clarke Drive
Cranbury, NJ 08512